巨噬细胞移动抑制因子在头颈癌中的作用及新治疗靶点:系统综述
本文系统综述了巨噬细胞移动抑制因子(MIF)在上呼吸消化道肿瘤中的实验与临床研究数据。基于现有文献,作者提出描述MIF参与头颈肿瘤细胞起始、进展、凋亡和增殖机制的生物分子模型,并描述了基于MIF拮抗剂和中和抗体的潜在治疗策略。结论认为MIF是未来治疗策略(联合或不联合放化疗)的有前景靶点。
要点
- MIF是一种促炎细胞因子,参与多种癌症的癌变、预后、增殖、侵袭和血管生成。
- 综述提出MIF参与头颈肿瘤起始、进展、凋亡和增殖的生物分子模型。
- MIF拮抗剂和中和抗体是潜在治疗策略,可联合或不联合放化疗。
核心结论
- MIF是未来头颈癌治疗策略的有前景靶点,可联合或不联合放化疗。
研究设计与样本
- 系统综述,回顾已发表的MIF在上呼吸消化道肿瘤中的实验和临床数据。
主要发现
- MIF参与多种癌症的癌变、疾病预后、肿瘤细胞增殖、侵袭和肿瘤诱导的血管生成。
- 提出了描述MIF参与头颈肿瘤细胞起始、进展、凋亡和增殖机制的生物分子模型。
临床怎么用
- 基于MIF拮抗剂和中和抗体的潜在治疗策略可用于头颈癌,可联合或不联合放化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in systemic, autoimmune, and inflammatory diseases, such as obesity, rheumatoid arthritis, and systemic lupus erythematosus. For the 2 past decades, MIF has been reported to participate in carcinogenesis, disease prognosis, tumor cell proliferation, invasion, and tumor-induced angiogenesis in many cancers. The purpose of this article is to review published experimental and clinical data for MIF and its involvement in upper aerodigestive tract cancers. Based on the current literature, we propose a biomolecular model describing the mechanisms underlying the involvement of MIF in the initiation, progression, apoptosis, and proliferation of head and neck tumor cells. In reference to this model, potential therapeutic approaches based on the use of MIF antagonists and neutralizing antibodies are described. It is concluded that MIF is a promising target for future therapeutic strategies, both with and without chemoradiation strategies.
引用
- Lechien JR, Nassri A, Kindt N, et al. Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review. Head Neck. 2017. PMID: 28963807. doi:10.1002/hed.24939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。